

OncoTherapy Science, Inc.

March 9, 2023

Announcement regarding termination of out-licensing contract and agreement to  
transfer patent rights of antibodies between our subsidiary company  
and Kyowa Kirin Co., Ltd.

OncoTherapy Science, Inc. (President & CEO: Junichi Shimada; hereinafter, “OncoTherapy”) announces that our subsidiary company, Immunas Pharma, Inc. made agreement with Kyowa Kirin Co., Ltd. to terminate the contract related to anti-amyloid  $\beta$  peptide antibodies for strategic reasons, which covers the rights for exclusive development, manufacturing, sales, etc., and includes the grant of exclusive license.

In addition, upon termination of the agreement, Immunas Pharma, Inc. has agreed to transfer the patent rights related to the anti-amyloid  $\beta$  peptide antibody (KHK6640) from Kyowa Kirin Co., Ltd.

KHK6640 was manufactured by Kyowa Kirin Co., Ltd. based on the monoclonal antibody established by Immunas Pharma, Inc. which selectively binds to amyloid  $\beta$  peptide (A $\beta$ ) aggregates. It is a humanized antibody used in clinical trials in Japan and EU. Recently, antibody drugs that target A $\beta$  have been approved for Alzheimer's disease, thus expectations are increasing for the efficacy of antibodies that target A $\beta$  aggregates particularly. KHK6640 has high selectivity for toxic A $\beta$  aggregates and is expected to inhibit the progression of Alzheimer's disease by neutralizing such A $\beta$  aggregates.

From now on, Immunas Pharma, Inc. will proceed out-licensing activities for anti-amyloid  $\beta$  peptide antibodies, including KHK6640, aiming to provide therapeutic agents for Alzheimer's disease.